Podcasts about cancer treatment

  • 1,533PODCASTS
  • 4,099EPISODES
  • 41mAVG DURATION
  • 1DAILY NEW EPISODE
  • Jul 4, 2025LATEST
cancer treatment

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about cancer treatment

Show all podcasts related to cancer treatment

Latest podcast episodes about cancer treatment

The Naked Scientists Podcast
The "Nanny Plate" debate, and the Neanderthal fat factory

The Naked Scientists Podcast

Play Episode Listen Later Jul 4, 2025 33:32


In the news, counting the calories: The UK government want shops to help us put 100 fewer calories in our baskets to beat obesity. So will it work? Also, archaeologists uncover the world's oldest fat factory - it turns out that Neanderthals were processing bones for their grease 125,000 years ago, but why? And on Mars the Curiosity rover captures close-up images of spiderweb-like patterns on the planet surface, but what made them? Listeners are also wondering whether green initiatives really do help to save the planet... Like this podcast? Please help us by supporting the Naked Scientists

The Common Sense MD
Making The Call: A Guide To Cancer Treatment Choices w/ Dr. Jamal Maatouk

The Common Sense MD

Play Episode Listen Later Jul 1, 2025 22:09


In this episode of The Common Sense MD, Dr. Tom Rogers welcomes back oncologist Dr. Jamal Maatouk for a compelling exploration of cancer care that goes well beyond the basics. Building on their previous holistic discussion of the cancer experience, Dr. Rogers and Dr. Maatouk dive deeper into how cancer treatment decisions are made—from surgery, chemotherapy, and radiation to cutting-edge targeted therapies and immunotherapies like CAR T.Dr. Maatouk shares her philosophy that there is no one-size-fits-all approach in oncology. She highlights the importance of truly getting to know each patient as a whole person, considering their wishes, unique biology, and even their spiritual outlook. The conversation unpacks the difference between immunotherapy and targeted therapy in an easy-to-understand way, as well as when and why oncologists might recommend gentler approaches like dose reductions or integrative support for quality of life.The doctors have an open, honest conversation about the value of second opinions, the evolving science of cancer, and the growing trend of patients taking an active role in their care—including the use of supplements and alternative therapies. Dr. Maatouk powerfully expresses her belief in the innate ability of the human body to heal, the role of hope and love in medicine, and her commitment to supporting each patient on their own unique healing journey.If you or a loved one are navigating cancer—or simply want a refreshing, compassionate take on modern medicine—this episode is an inspiring reminder that healing is possible, and that true care starts with listening, empathy, and hope.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

ASCO Daily News
Innovations in GU Cancer Treatment at ASCO25

ASCO Daily News

Play Episode Listen Later Jun 26, 2025 29:46


Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Lillian McDermott
Henning Saupe, MD, Why Metabolic Support Is Key in Cancer Treatment

Lillian McDermott

Play Episode Listen Later Jun 25, 2025 59:02


Can addressing the body's metabolism really make a difference in cancer care? Henning Saupe, MD, author of Holistic Cancer Medicine, and founder of Arcadia Praxisklinik, believes it can, and must. After witnessing the toll conventional treatments took on his mother, Dr. Saupe was inspired to explore a gentler, more supportive path. He now helps patients […]

Fraternity Foodie Podcast by Greek University
Ruth Fein: Supporting Someone Going Through Cancer

Fraternity Foodie Podcast by Greek University

Play Episode Listen Later Jun 25, 2025 27:05


Supporting someone going through cancer - what's the best way to do it when you don't know what to say? Ruth Fein has a bunch of interesting titles. Medical/science reporter. Award-winning author. Patient engagement leader. Motivational speaker. Ruth is a globally recognized patient advocate leader with a proven track record bringing together the voice of the patient, not-for-profit sector, industry and academia in the hematology/oncology space. In episode 579 of the Fraternity Foodie Podcast, we find out why Ruth chose Utica College for her undergraduate experience, how her rare blood cancer shaped her work as a journalist and patient advocate, what inspired her to write The Big C² and how it's different from other books, what is the best way to support someone going through cancer, how you can recognize red flags in your own health, what are some phrases to avoid when talking to someone who has cancer, what tools or perspectives have helped people she's interviewed to move forward, how to make the most of that time with doctors and truly advocate for themselves, and what college students need to know about the future of cancer treatment.

The Common Sense MD
Cancer Treatment w/ Dr. Jamal Maatouk

The Common Sense MD

Play Episode Listen Later Jun 24, 2025 25:59


In this episode of The Common Sense MD, Dr. Tom Rogers welcomes esteemed oncologist Dr. Jamal Maatouk for an inspiring and deeply honest conversation about cancer treatment, the role of lifestyle in health, and the importance of treating the whole person—mind, body, and soul. Dr. Maatouk shares her unique journey from Lebanon to the U.S., the challenges and rewards of practicing oncology, and her faith-driven approach to guiding patients through both healing and end-of-life care. Together, they explore the rising trends in cancer diagnoses, the impact of environment and mindset, and how physicians can balance science, art, and empathy in their practices. Join this powerful discussion on hope, healing, and the common-sense steps we can all take to prevent disease and live more vibrant lives.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

Health Newsfeed – Johns Hopkins Medicine Podcasts
Which types of cancer treatment are impacted by the gut microbiome? Elizabeth Tracey reports

Health Newsfeed – Johns Hopkins Medicine Podcasts

Play Episode Listen Later Jun 23, 2025 1:03


More types of gut bacteria, or greater diversity, the healthier your microbiome. That's one message of a recent review looking at the impact of microbiome health on cancer. Kimmel Cancer Center director William Nelson at Johns Hopkins explains how gut … Which types of cancer treatment are impacted by the gut microbiome? Elizabeth Tracey reports Read More »

Walk, Don't Run to the Doctor with Miles Hassell, MD
36. The (Not So) Surprising Role of Exercise in Cancer Treatment

Walk, Don't Run to the Doctor with Miles Hassell, MD

Play Episode Listen Later Jun 20, 2025 16:20


What if a free, side-effect-free therapy could significantly improve your cancer survival— and even help prevent recurrence? In this episode, we explore the powerful, research-backed role of exercise in cancer prevention and treatment, centered around the recent CHALLENGE trial published in The New England Journal of Medicine. Here is the link to that study: https://www.nejm.org/doi/10.1056/NEJMoa2502760 Dr. Hassell shares groundbreaking findings showing that moderate, consistent exercise significantly reduces cancer recurrence and mortality — particularly in colon cancer survivors — when added to conventional treatments. More than just prevention, movement is positioned as a critical treatment tool that enhances immunity, reduces inflammation, balances hormones, and even boosts mental health. Key Takeaways: Exercise led to a 37% lower risk of death in colon cancer patients (CHALLENGE trial). Benefits appear as early as 1 year into a structured program (as little as brisk walking!). Sedentary lifestyles are now considered nearly as dangerous as smoking. Even 1-minute workouts a few times a day can start improving immune function. The “number needed to treat” for exercise is dramatically better than many standard medical therapies. Physical activity also reduces risk of diabetes, heart disease, depression, frailty, and more. Social, playful exercise (like frisbee or ping pong) boosts both body and mind — and reduces loneliness. Watch now to discover how just a few minutes of movement a day could change — or even save — your life. #CancerTreatment #ExerciseAndCancer #PreventativeHealth #ChallengeTrial #LifestyleMedicine #WalkDontRunPodcast #MentalHealth #ChronicDiseasePrevention More references can be found at www.GreatMed.org Would you like Dr. Hassell to answer your question on the air?  Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter.  We love to hear from you.  This podcast is sponsored by our generous listeners.  Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229

Radiolab
The Shark Inside You

Radiolab

Play Episode Listen Later Jun 18, 2025 28:53


This is episode three of Swimming with Shadows: A Radiolab Week of Sharks.Today, we take a trip across the world, from the south coast of Australia to … Wisconsin. Here, scientists are scouring shark blood to find one of nature's hidden keys, a molecular superhero that might unlock our ability to cure cancer: shark antibodies. They're small. They're flexible. And they can fit into nooks and crannies on tumors that our antibodies can't.We journey back 500 million years to the moment sharks got these special powers and head to the underground labs transforming these monsters into healers. Can these animals we fear so much actually save us? Special thanks to Mike Criscitiello, David Schatz, Mary Rose Madden, Ryan Ogilvie, Margot Wohl, Sofi LaLonde, and Isabelle Bérubé.EPISODE CREDITS: Reported by - Becca BresslerProduced by - Becca Bressler and Matt KieltyOriginal music from - Matt Kielty and Jeremy BloomSound design contributed by - Matt Kielty, Jeremy Bloom, and Becca Bresslerwith mixing help from - Jeremy BloomFact-checking by - Diane Kellyand Edited by  - Pat WaltersSignup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

The Art of Living Well Podcast
E274: Live Longer, Heal Faster: Stem Cell Therapy & Anti-Aging Insights with Joshua Ketner

The Art of Living Well Podcast

Play Episode Listen Later Jun 18, 2025 60:02


Stem Cell Therapy, Longevity & Regenerative Healing with Joshua Ketner Josh Ketner is a pioneer in the field of regenerative medicine. Josh is not only the insightful author of 'The Ultimate Guide to Stem Cell Therapy,' but he's also the visionary founder of Dream Body Clinic, nestled in tropical Puerto Vallarta, Mexico. At Dream Body Clinic, Josh and his team specialize in cutting-edge treatments like mesenchymal stem cell therapies, along with Human Growth Hormone (HGH) and other innovative age-defying medicines. In this powerful episode, we sit down with Joshua Ketner, founder of DreamBody Clinic in Mexico, to explore how stem cell therapy is transforming the future of health and longevity. Episode highlights: ✔ How stem cells work (hint: they're not what you think) ✔ Why patients are traveling to Mexico for affordable regenerative care ✔ Conditions treated: arthritis, autoimmune diseases, organ issues & more ✔ Success stories that defy the odds and how treatments can add quality years to your life. ✔ How hormone therapy & DNA methylation testing support anti-aging ✔ The truth about safety, U.S. regulations, and stem cell myths Chapters   06:23 Understanding Stem Cells, the sciene and Their Function 17:31 Common Conditions Treated at DreamBody Clinic 19:40 Addressing Skepticism and Success Stories 20:39 Treatment Process and Patient Experience 22:34 Safety and Side Effects of Treatments 30:27 Safety and Efficacy of Stem Cells in Cancer Treatment 33:26 Success Stories: Overcoming Autoimmune Conditions 36:55 Preventative Measures for Longevity 41:34 The Importance of Blood Work for Weight Loss 43:06 Understanding Treatment Costs and Transparency   This conversation breaks down complex science into actionable insights for anyone seeking pain relief, age reversal, and optimal health. Helpful links and resources: Learn about Dream Body Clinic https://www.youtube.com/@DBCStemCells Purchase Joshua's book here FB: facebook.com/dreambodyclinic IG: @clinicdreambody

Navigating Cancer TOGETHER
The Birth of a Wig Resource for Women of Color with Dianne Austin

Navigating Cancer TOGETHER

Play Episode Listen Later Jun 18, 2025 33:45


Has cancer ever made you feel like you're losing a piece of yourself, especially your identity? Imagine facing hair loss from treatment, only to find the wig options available don't reflect who you are. This isn't just about hair; it's about dignity, self-esteem, and seeing yourself truly represented.In this powerful rebroadcast, join your host, Talaya Dendy, on Navigating Cancer TOGETHER as she welcomes the incredible Dianne Austin. A breast cancer survivor herself, Dianne co-founded Coils to Locs, a groundbreaking initiative born out of a deeply personal struggle. Prepare to be inspired by her journey to transform the wig industry and support women of color facing hair loss due to cancer and other medical conditions.

TD Ameritrade Network
CAI CEO on Using AI to Personalize Cancer Treatment

TD Ameritrade Network

Play Episode Listen Later Jun 18, 2025 11:32


Caris Life Sciences (CAI) CEO Brian Brille discusses their IPO and using AI in medical care. Caris is a precision oncology company that offers personalized treatment using genomic sequencing and data. “We're a pioneer in genomics…more information equals more power.” He explains the company's process and why AI is a useful tool in the field. He also talks about their unusual partnership structures with other companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Breaking Health
Episode: 173 - Matt Bettonville on Oncological Research and Drug Discovery Investment

Breaking Health

Play Episode Listen Later Jun 17, 2025 27:46


In this episode of Breaking Health, host Steve Krupa speaks with Matt Bettonville, investor at Yosemite, about the state of oncology research and his hunt for investments in discovery and treatment tools. Bettonville delves into the key to cancer treatment, where deals are flowing towards in the market, and how the AI revolution is helping with drug discovery and cancer treatment breakthroughs. He also discusses the complications (and frustrations) of making treatments affordable, finding new targets in primary cancers most frequently seen in the population, and the importance of early detection. Links from this episode:  HealthEdgeYosemite  

Here For The Craic with Emma Neill
Romeo on going through cancer treatment at 18

Here For The Craic with Emma Neill

Play Episode Listen Later Jun 16, 2025 63:40


Big thanks to Romeo for joining me on the podcast today❤️ Donate to Cancer Fund For Children https://www.justgiving.com/page/graeme-neill-1732027521897 Find out more about the 26M2M challenge https://www.26m2m.com/ Find out more about the charity https://cancerfundforchildren.com/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ask Julie Ryan
#647 - Spirit's ENERGY HEALING Method Defies Logic & WORKS!

Ask Julie Ryan

Play Episode Listen Later Jun 13, 2025 66:38


EVEN MORE about this episode!Let's explore the incredible intersection of spiritual insight and physical healing! From foot pain relief in Australia to emotional support during brain cancer treatment in Connecticut, witness how intuition, visualization, and collective energy can shift pain and promote healing.Discover the hidden emotional roots of illness, how intuitive scans reveal what doctors often can't, and why our pets may be mirroring our health. Whether it's helping a child with special needs, soothing an anxious dog owner, or clearing energy blocks that contribute to chronic symptoms—this episode is a moving journey into what's truly possible when we combine intention with intuition.Plus, get a sneak peek at my upcoming Angelic Attendant Training—an immersive experience that could change your life. Don't miss this transformative episode that just might open your mind to a whole new way of healing!Episode Chapters:(0:00:01) - Psychic Healing(0:14:40) - Cancer Healing Energy Session(0:23:56) - Healing Energy for Eye Conditions(0:36:54) - Group Session for Hearing Loss(0:49:54) - Healing Consultation(0:59:09) - Healing Energy for Cancer Treatment(1:05:36) - Messages From Sweet Home Alabama➡️Subscribe to Ask Julie Ryan YouTube➡️Subscribe to Ask Julie Ryan Español YouTube➡️Subscribe to Ask Julie Ryan Português YouTube➡️Subscribe to Ask Julie Ryan Deutsch YouTube➡️Subscribe to Ask Julie Ryan Français YouTube✏️Ask Julie a Question!

The Spectrum of Health with Dr. Christine Schaffner
The Interplay of Quantum Physics and Health with Dr. Jack Tuszynski | Episode 292

The Spectrum of Health with Dr. Christine Schaffner

Play Episode Listen Later Jun 12, 2025 42:30


In this thought-provoking episode of the Spectrum of Health podcast, Dr. Christine Schaffner welcomes Dr. Jack Tuszynski, a leading biophysicist and researcher in the emerging field of quantum biology. This conversation, recorded during the Quantum Coherence Medicine Masterclass, explores the fundamental role of quantum mechanics in human biology and consciousness.   Dr. Tuszynski shares fascinating insights into microtubules, cellular communication, and the science behind how coherence and quantum fields may influence healing. Together, they discuss the convergence of physics and medicine—and how future health innovations could be shaped by our deepening understanding of quantum processes in the body.  

#plugintodevin - Your Mark on the World with Devin Thorpe
Transforming Cancer Treatment: Nicole Paulk's Bold Mission with Siren Biotechnology

#plugintodevin - Your Mark on the World with Devin Thorpe

Play Episode Listen Later Jun 12, 2025 25:50


Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Modern Mindset with Adam Cox
540 - Dr Juho Jalkanen on a New Blood Cancer Trail That Could Revolutionise Treatment

Modern Mindset with Adam Cox

Play Episode Listen Later Jun 12, 2025 7:23


Rory McGowan is joined by Dr Juho Jalkanen from Faron Pharmaceuticals. In this episode they discuss a new blood cancer trial has shown highly promising results, particularly for patients who have relapsed or live with hard-to-treat forms of the disease. https://faron.com/ 

Keeping Abreast with Dr. Jenn
99: The Shocking Truth About Cholesterol, Cancer & Prescription Drugs with Dr. Magaziner

Keeping Abreast with Dr. Jenn

Play Episode Listen Later Jun 10, 2025 73:21


In this powerful episode of Keeping Abreast, I sit down with renowned functional medicine pioneer Dr. Allen Magaziner to explore his transformative journey into integrative care. From the early days of facing resistance in a conventional medical landscape to building a thriving holistic practice, Dr. Magaziner shares how personal experiences—particularly his mother's health struggles—led him to challenge the status quo.Together, we unpack the many flaws in our current medical system, including the dangers of overdiagnosis, the overreliance on prescription medications, and the urgent need to prioritize health over disease management. This conversation dives deep into the misunderstood world of cholesterol, inflammation, and the often-overlooked role of nutritional deficiencies—especially vitamin D—in both cancer prevention and treatment.Listeners will be inspired by Dr. Magaziner's passion for integrative oncology, his insights into lifestyle medicine, and his message of hope for anyone facing cancer. The episode also honors the legacy of Suzanne Somers, who bravely championed hormone replacement therapy and encouraged women to reclaim their health after cancer. In This Episode, You Will Learn:-Dr. Magaziner's path into functional medicine began with his mother's illness-The limitations of conventional medicine spurred his shift toward integrative care-Overdiagnosis and prescription drug overuse are harming more than helping-Cholesterol is essential to health—context and nuance matter-Vitamin D regulates over 2,000 genes, including many with anti-cancer properties-Maintaining optimal vitamin D levels (>90 ng/mL) is critical in cancer care-Integrative oncology can radically improve both outcomes and quality of life-Repurposed medications, such as metformin, show promise in cancer therapy-Fear inhibits healing—support, mindset, and curiosity are vital-Suzanne Somers' legacy continues to empower women's wellness journeys 

Dog Cancer Answers
Dog Cancer Success Story: Dunbar's Triumph Over Lung Cancer | Dr. Katie Berlin and Tara Diehl #285

Dog Cancer Answers

Play Episode Listen Later Jun 9, 2025 41:04


Meet Tara Diehl and Dr. Katie Berlin and soak in hope and love as they discuss the inspiring story of Dunbar, Tara's 12-year-old dog diagnosed with primary undifferentiated pulmonary carcinoma. From the initial harrowing diagnosis to numerous treatments, including surgery, chemotherapy, and the promising effects of Palladia, Dunbar's story is a testament to hope, resilience, and the power of a dedicated dog mom … and dog insurance! The discussion highlights the importance of pet insurance, holistic care approaches, and the invaluable bond between pets, their owners, and veterinary teams. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Links: Dog Cancer Survival Guide - https://dogcancerbook.com/ Apocaps – https://apocaps.com/ Chapters: 00:00 Living in the Moment: Dunbar's Journey Begins 01:03 The Diagnosis: A Vet Tech's Worst Fear 03:18 Dunbar's Personality Shines Through 06:19 The Battle with Cancer: Treatment and Hope 08:52 Insurance and Financial Relief 14:04 A Comprehensive Approach: Supplements and Alternative Therapies 17:16 Dunbar's Resilience and Joy 18:09 Dog Cancer Resources and Support 18:38 The Impact of Attitude on Treatment 19:10 Dunbar's Medical Journey 23:57 Dunbar's Miraculous Recovery 25:26 Dunbar's Current Life and Activities 26:40 The Emotional Bond with Veterinary Teams 29:47 Final Thoughts and Encouragement 33:55 Closing Remarks and Resources   Get to know Dr. Katie Berlin: https://www.dogcancer.com/people/katie-berlin-dvm/ Get to know Tara Diehl: https://www.dogcancer.com/people/tara-diehl/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

The Podcast by KevinMD
How functional precision oncology is revolutionizing cancer treatment

The Podcast by KevinMD

Play Episode Listen Later Jun 6, 2025 23:13


Physician and clinical researcher Chris Apfel discusses his article, "Functional precision oncology: a game changer in cancer therapy." Chris explains that functional precision oncology takes a highly personalized approach by testing a patient's live tumor cells outside the body (ex-vivo) against a panel of cancer drugs to directly observe which treatments are most effective against that specific cancer. This method, he argues, can significantly improve cancer response rates and survival while reducing costs and unnecessary side effects, by moving beyond the limitations of standard pathology (which identifies cancer type but not optimal treatment) and genomic sequencing (which identifies mutations but provides actionable targets for only a minority of patients). Chris recounts the history of functional testing, its initial promise, its decline with the rise of next-generation sequencing, and its current resurgence, supported by studies demonstrating its high predictive accuracy for clinical outcomes. Despite its potential to complement genomics and truly personalize care, he notes that functional precision oncology faces slow adoption due to its general absence from standard NCCN treatment guidelines, hospital restrictions on external tissue testing, and a systemic preference in health care for standardization over innovative, individualized approaches. Chris strongly encourages patients, particularly those facing difficult or unresponsive cancers, to educate themselves about functional precision oncology and actively advocate for access to these tests. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise and it's part of Microsoft Cloud for Healthcare–and it's built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

pharmaphorum Podcast
Servier's ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo

pharmaphorum Podcast

Play Episode Listen Later Jun 5, 2025 9:25


At ASCO 2025, Servier presented data in the IDH-mutated cancer space. Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company's Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress this year. Listen to this and other interviews from ASCO 2025 here.

The Health Ranger Report
Brighteon Broadcast News, June 4, 2025 – Biosludge terrorism threatens America; Sec. Kennedy defends launching vaccines TODAY based on clinical trials scheduled in THE FUTURE

The Health Ranger Report

Play Episode Listen Later Jun 4, 2025 178:24


Register free at https://brightu.com to watch the full Healing Revolution stream - Breaking News and Upcoming Segments (0:00) - Microscopy of Bio Sludge (2:04) - Bio Sludge as a Vector for Bioterrorism (4:03) - Details of the Chinese Couple's Case (7:23) - Potential for Bioterrorism and EPA's Role (11:51) - Microscopy of Bio Sludge: Dry Condition (17:54) - Microscopy of Bio Sludge: Incubated Condition (39:25) - Moderna Vaccine Approval and RFK Jr. (53:26) - Elon Musk's Criticism of Trump's Bill (1:07:07) - Ukraine War and Financial Corruption (1:12:41) - AI and Humanity's Future (1:17:40) - Self-Awareness in Life Forms (1:20:40) - Artificial Intelligence and Self-Awareness (1:27:51) - The Potential Dangers of AI (1:32:30) - AI's Impact on Infrastructure and Society (1:37:07) - The Role of Light in Healing (1:46:09) - The Healing Revolution Docu Series (1:47:06) - The Importance of Combining Therapies (1:50:03) - The Role of Light in Activating Nutrients (1:51:34) - The Impact of Light on Cancer Treatment (2:33:08) - The Role of Light in Detoxification (2:35:26) - LED vs. Incandescent/Halogen Bulbs (2:36:33) - Wavelengths and Their Therapeutic Benefits (2:38:13) - Dual LED Technology and Natural Intelligence (2:39:45) - Practical Applications and Humanitarian Efforts (2:42:09) - Healing Revolution Course and Additional Resources (2:45:53) - Long COVID Study and Remission Rates (2:47:42) - Final Thoughts and Call to Action (2:50:30) - Health Ranger's Preparedness Tips (2:51:47) - Iodine Supplements and Their Benefits (2:56:14) - Conclusion and Final Remarks (2:58:12) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Integrative Cancer Solutions with Dr. Karlfeldt
Revolutionizing Cancer Treatment: Dr. Apfel's Onca Test and the Power of Personalized Therapy

Integrative Cancer Solutions with Dr. Karlfeldt

Play Episode Listen Later Jun 4, 2025 39:05


In this podcast episode of Integrative Cancer Solutions Dr. Karlfeldt interviews Dr. Chris Apfel about his integrative approaches to cancer treatment. Dr. Apfel shares his journey from traditional medicine to integrative oncology, sparked by his father's lung cancer diagnosis. This personal experience led him to question conventional cancer treatments after learning about their low success rates, particularly for stage four lung cancer. Dr. Apfel discusses his development of the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments. This test evaluates a wide range of treatments including chemotherapies, targeted therapies, and repurposed drugs. He emphasizes the importance of avoiding ineffective treatments that can harm the immune system and diminish quality of life, while highlighting the potential of repurposed drugs like statins, Metformin, and Itraconazole. The conversation addresses tumor heterogeneity and the need for representative biopsy samples, particularly from metastatic sites. Dr. Apfel explains that the Onca test is commercially available, with discounts offered to patients willing to share their data for research purposes. He discusses various methods for obtaining tumor samples and the importance of timing in the collection process.Dr. Apfel emphasizes patient advocacy and the need for patients to be informed about their treatment options. He notes that the Onca test can double the odds of a positive tumor response and significantly increase median survival rates. The podcast concludes with Dr. Apfel expressing interest in collaborating with Dr. Folt's center to help more cancer patients through this innovative approach to personalized cancer treatment.About Dr Chris Apfel:Chris Apfel, MD, PhD, MBA is a physician and clinical researcher with over 100 published papers, including a six-factor clinical prediction model published in NEJM that led to the development of The Apfel Score, a clinical calculator used universally to predict the risk of postoperative nausea and vomiting, and Dr Apfel's ultimate recruitment to the US and the University of California, San Francisco.Dr. Apfel was driven to revolutionize the field of cancer patient treatment after losing his mother to a long battle with ovarian cancer and his father to lung cancer. Witnessing their suffering inspired him leave the clinical department at UCSF to develop more efficient ways to identify the best treatment plans for cancer patients.Dr Apfel received his MD and PhD from the University of Giessen in Germany and his MBA from Wharton at the University of Pennsylvania. He is the founder and CEO of SageMedic.Dr. Apfel developed the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments, potentially doubling the odds of positive tumor response.Personal experience with his father's lung cancer led Dr. Apfel to question conventional treatments after discovering their low success rates for advanced cancers.The Onca test evaluates chemotherapies, targeted therapies, and repurposed drugs like statins and Metformin, which have shown promising results in cancer treatment.Tumor heterogeneity makes it crucial to obtain representative biopsy samples, particularly from metastatic sites, to avoid ineffective treatments.Patient advocacy is essential in cancer treatment, as patients need to make informed decisions about tissue handling before surgery and find oncologists willing to consider alternative treatments based on test results.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Navigating Cancer TOGETHER
National Cancer Survivor Month: What's at the Heart of Survivorship?

Navigating Cancer TOGETHER

Play Episode Listen Later Jun 4, 2025 54:41


In this special episode of Navigating Cancer TOGETHER, host Talaya Dendy honors National Cancer Survivor Month by sharing deeply personal stories from eight incredible cancer survivors, including herself. The guests (Grisel Scarantino, Russ Hedge, Mary Wells, Tom Reaoch, Annamaria Scaccia, Terry Tucker, and Zoraida Morales) share deeply personal stories about their unique cancer journeys, revealing how their experiences transformed their perspectives on life, purpose, and personal growth. Each survivor discusses the challenges they faced after treatment, including physical side effects, emotional struggles, and the process of redefining their identity beyond their cancer diagnosis.Dive deeper into the themes of this episode in our companion blog post: https://www.ontheotherside.life/national-cancer-survivor-month-unpacking-the-dynamic-discoveries-of-life-after-cancerLearn more about National Cancer Survivor Month. https://cancercontrol.cancer.gov/ocs/about/survivorship-month

Sarcoma CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Sarcoma CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Lung Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Lung Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Chronic Myelogenous Leukemia CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Chronic Myelogenous Leukemia CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Thyroid Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Thyroid Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Triple Negative Breast Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Triple Negative Breast Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

All CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

All CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Glioblastoma CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Glioblastoma CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Colorectal Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Colorectal Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Metastatic Breast Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Metastatic Breast Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Pancreatic Cancer CancerCare Connect Education Workshops
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care

Pancreatic Cancer CancerCare Connect Education Workshops

Play Episode Listen Later Jun 2, 2025 51:55


- Disproportionate Burden of Cancer & Infectious Diseases on People of Color - Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care - Influence of the Local & Regional Environment in Which You Live - How Race May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management - Tips to Find Your Best Care Team - Access to Cancer Treatment in the LGBTQI+ Community - The Role of Housing, Cost of Cancer Treatment & Follow-Up Care on Your Health - Food & Pharmacy Deserts - Food Insecurity: Tips to Increase Your Access to Health Promoting Nutrition - Job Commitments, Access, Transportation to Treatment & More - How Telehealth May Help in Advancing Your Health Equity - Tips to Cope with Health Care Disparities: Valuing Your Identity - Guidelines to Communicate with Your Health Care Team - Questions for Our Panel of Experts

Don't Ignore the Nudge
God's Kingdom, God's Way Part 2

Don't Ignore the Nudge

Play Episode Listen Later Jun 1, 2025 43:05


Have you ever wished that there would be a world renown doctor who not only was great at his profession, but also loved the Lord??  Well, today you'll meet Dr. Tony Jimenez, founder and Chief Medical Officer of Hope4Cancer, one of the best places in the world to get treatment.  Where does the Lord fit in?  IN AND THROUGHOUT our whole conversation.  Enjoy!Reach Out to Me:Website: www.dontignorethenudge.comPatreon: www.patreon.com/dontignorethenudgeIG: @dontignorethenudgepodcastPrivate FB group to WATCH interviews: www.dontignorethenudge.com/facebook__________________________________________________________________________________________Business/Personal Coaching with Cori:www.corifreeman.com(951) 923-2674

Five To Thrive Live
Building Liver Health During and After Cancer Treatment

Five To Thrive Live

Play Episode Listen Later May 27, 2025 29:43


The liver is one of the hardest working organs in the human body performing hundreds of critical functions necessary for optimal health. It's also important to have the liver function properly during and after cancer treatment. On this show, Lise and Karolyn will describe how to support the liver so it can help you get through treatment and thrive after your cancer diagnosis.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Don't Ignore the Nudge
God's Kingdom, God's Way Part 1

Don't Ignore the Nudge

Play Episode Listen Later May 25, 2025 32:50


Have you ever wished that there would be a world renown doctor who not only was great at his profession, but also loved the Lord??  Well, today you'll meet Dr. Tony Jimenez, founder and Chief Medical Officer of Hope4Cancer, one of the best places in the world to get treatment.  Where does the Lord fit in?  IN AND THROUGHOUT our whole conversation.  Enjoy!Reach Out to Me:Website: www.dontignorethenudge.comPatreon: www.patreon.com/dontignorethenudgeIG: @dontignorethenudgepodcastPrivate FB group to WATCH interviews: www.dontignorethenudge.com/facebook__________________________________________________________________________________________Business/Personal Coaching with Cori:www.corifreeman.com(951) 923-2674

The Naked Scientists Podcast
Curing mosquitoes' malaria, and the history of our units

The Naked Scientists Podcast

Play Episode Listen Later May 23, 2025 33:36


In this edition of The Naked Scientists: The new drug that cures mosquitoes of malaria. Intrigued? You'll see why scientists have done this, in just a minute. Also, the Microsoft AI system set to revolutionise weather forecasting, so you can plan that barbecue with impunity in future! And, 150 years of the metre, kilo and second: how science finally agreed on a definition for some of our most important units... Like this podcast? Please help us by supporting the Naked Scientists

DAV Podcast
Protecting progress, VA funding and the future of cancer care for veterans

DAV Podcast

Play Episode Listen Later May 22, 2025 9:43


In this episode of the DAV Podcast, host Brian Buckwalter speaks with Dr. Ben Park, Director of the Vanderbilt Ingram Cancer Center, about the critical state of cancer research and its direct impact on military veterans. Dr. Park highlights the groundbreaking progress in cancer treatment, including innovative cellular therapies performed at the Nashville VA Hospital, and expresses grave concerns over recent, unprecedented funding cuts. He emphasizes that these cuts not only jeopardize patient lives and the continuation of life-saving research but also hinder the training of future medical professionals, ultimately undermining the commitment to provide veterans with the best possible care they deserve.

The Medical Sales Podcast
The Future of Cancer Treatment And Medical Sales

The Medical Sales Podcast

Play Episode Listen Later May 21, 2025 35:31


Courtney Turich shares the journey of Cooler Heads, the startup behind a scalp cooling device that helps chemo patients keep their hair and dignity.   From early challenges to reaching over 100 infusion centers, she reveals how awareness, advocacy, and social media-fueled their growth.   We explore the emotional impact of scalp cooling, the barriers to oncologist adoption, and the company's commitment to patient education.   Courtney also offers career advice for breaking into medical sales, thriving in startups, and leading with purpose.   This is a must-listen for anyone who wants to build a mission-driven career, create a real impact in healthcare, or understand what it takes to grow a successful medical startup.   Connect with Courtney: LinkedIn Connect with Me: LinkedIn   Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

WSJ Tech News Briefing
Electricity Powers New Frontier in Cancer Treatment

WSJ Tech News Briefing

Play Episode Listen Later May 19, 2025 11:49


Long used to power implantable devices like pacemakers, electricity is now gaining traction as a possible treatment for diseases such as cancer. WSJ health reporter Brianna Abbott tells us how clinical trials are showing early promise. Plus: Meta is contending with an ‘epidemic of scams' on its platforms as criminals flood Instagram and Facebook. WSJ tech reporter Jeff Horwitz explains how the company is responding. Sign up for the WSJ's free Technology newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Intelligent Medicine
Intelligent Medicine Radio for May 17, Part 2: "Poop Pill"

Intelligent Medicine

Play Episode Listen Later May 19, 2025 42:18


Is the “poop pill” a possible treatment for small intestinal bacterial overgrowth (SIBO)? Pro-mask, pro-lockdown, pro-vax words come back to haunt their authors as Covid response critics appointed to key HHS positions; MAHA influencer Dr. Casey Means replaces original Surgeon General nominee; Rating Trump's new vaccine czar, oncologist Vinay Prasad; Is Laetrile effective for cancer? If you're eating a diet rich in fruits and vegetables, do you still need probiotics? Researchers tap an unusual source for antivenom against deadly snakebites—a snake handler who's survived multiple poisonings.

Integrative Cancer Solutions with Dr. Karlfeldt
Frequency Medicine: How NASA Research Led to Breakthrough Cancer Treatment Technology with Dr. Luba Diangar

Integrative Cancer Solutions with Dr. Karlfeldt

Play Episode Listen Later May 14, 2025 50:27


In this episode of Integrative Cancer Solutions, Dr. Karlfeldt interviews Dr. Luba Diangar about her innovative frequency device developed after her work with NASA. Dr. Luba explains how her background in life support systems and micro-nutrition research at NASA led her to develop a medical device that can both diagnose and treat underlying health issues. After analyzing thousands of body scans, she created a programmable device called Mono Core, that addresses various health concerns, particularly anxiety, sleep problems, and emotional issues. Dr. Luba discusses the application of her frequency device in cancer treatment, emphasizing the importance of individualized approaches. The device helps identify patterns in cancer patients, such as previous head injuries and emotional trauma that may contribute to immune system dysfunction. She explains how the technology produces customized frequency groups tailored to each patient's specific needs, addressing not only the cancer itself but also underlying infections and emotional factors that may be compromising the immune system. The podcast highlights how the device incorporates AI technology that can be used either passively or actively to treat various health issues. Dr. Luba explains that the gentle approach helps restore memory, balance brain function, and strengthen the immune system without harsh side effects. She shares several success stories, including a young man with liver cancer who showed significant improvement and a stage 4 adenocarcinoma patient who experienced excellent results under the care of a naturopathic doctor using the device. Dr. Luba and Dr. Feld conclude by discussing the future potential of frequency medicine as a complementary or alternative approach to traditional cancer treatments. They emphasize the device's ability to create an optimal environment for the body to recover by supporting its innate intelligence and strengthening the immune system to prevent cancer spread. Dr. Luba suggests that this technology represents a promising direction in integrative cancer care that addresses the whole person rather than just targeting the disease. The frequency medicine approach focuses on creating an optimal environment for the body to recover by supporting its innate intelligence rather than attacking the cancer directly.Dr. Luba developed a frequency device called Mono Core based on her NASA research that can diagnose and treat underlying health issues, including cancer.The device identifies patterns in cancer patients such as head injuries and emotional trauma, then produces individualized frequency treatments to strengthen the immune system.New AI programs in the device allow for both passive and active treatment approaches that gently restore memory, balance brain function, and address various health concerns.Dr. Luba shared success stories including significant improvement in a liver cancer patient and excellent results in a stage 4 adenocarcinoma case.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Navigating Cancer TOGETHER
Navigating Bladder, Melanoma, and Skin Cancer with Dr. Eanelli

Navigating Cancer TOGETHER

Play Episode Listen Later May 14, 2025 51:11


Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.

The A.M. Update
ASK IZZY: Is THIS New Cancer Protocol Legit?! | No Suck Saturday #041

The A.M. Update

Play Episode Listen Later May 10, 2025 37:13


In this episode of No Suck Saturday, hosts Aaron and Bella discuss a variety of topics ranging from uplifting news stories to health insights. They celebrate Mother's Day with inspiring stories of families graduating together and delve into the fascinating science of microchimerism, highlighting the deep connections between mothers and their children. The conversation shifts to social interactions across generations, showcasing a TikTok trend of young people engaging with older adults. Bella answers health-related questions in the Ask Izzy segment, covering red light therapy, alternative cancer treatments, and the myths surrounding parasite cleanses. The episode concludes with personal highlights and reflections on parenting and life choices.    

CNN News Briefing
Trump trade negotiations, new cancer treatment study, Met Gala preview & more

CNN News Briefing

Play Episode Listen Later May 5, 2025 6:51


President Donald Trump weighed in on talks with US trade partners. Europe unveiled a push to attract researchers amid America's changes to science policy. The Department of Homeland Security is offering undocumented migrants an incentive to self-deport. Researchers found a treatment that allows certain cancer patients to avoid surgery. And, what you can expect at fashion's biggest night out! Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Health Ranger Report
Brighteon Broadcast News, May 2, 2025 - Trump announces total TRADE EMBARGO against China, NO exceptions… SHOCK DOCTRINE supply chain Armageddon!

The Health Ranger Report

Play Episode Listen Later May 2, 2025 169:20


- Trump's Trade Embargo Announcement (0:10) - Impact on Global Trade and BRICS (4:08) - Challenges for U.S. Retailers and Manufacturers (16:32) - China's Strategic Response and Cultural Resilience (16:49) - Geopolitical Implications and Economic Collapse (34:05) - Preparation and Survival Strategies (1:06:23) - Special Reports and Additional Resources (1:14:50) - Mike Adams' Analysis of Geopolitical Factors (1:26:57) - Trump's Strategic Priorities and Western Europe's Reaction (1:30:44) - China's Strategic Advancements and Economic Dominance (1:37:11) - China's Long-Term Strategic Goals and Military Capabilities (1:40:57) - The Petrodollar System and Its Imminent Collapse (1:48:16) - The Rise of the BRICS Nations and the BRICS Blockchain (1:57:51) - Beljanski Foundation's Research and Clinical Trials (2:03:26) - The Importance of Nutritional Milestones and Health Choices (2:23:24) - The Future of Cancer Treatment and Research (2:29:31) - The Role of Technology and Information in Health (2:43:18) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Dr. Joseph Mercola - Take Control of Your Health
DMSO: A Natural Compound's Potential in Cancer Treatment - AI Podcast

Dr. Joseph Mercola - Take Control of Your Health

Play Episode Listen Later May 2, 2025 10:23


Story at-a-glance Versatile therapeutic benefits — Dimethyl sulfoxide (DMSO) is a potent compound known for treating a wide range of conditions, including chronic pain, stroke recovery, tissue damage, autoimmune disorders, various skin conditions, and complex infections Unique role in cancer care — DMSO's distinctive properties enable it to support the body in combating cancer while safeguarding healthy cells from the harmful effects of chemotherapy and radiation Enhanced chemotherapy delivery — When paired with chemotherapy, DMSO improves the drug's ability to penetrate cancer cells that are typically inaccessible, significantly boosting treatment effectiveness Lower doses, reduced toxicity — By enhancing the potency of chemotherapy, DMSO allows for the use of lower doses, substantially reducing the toxic side effects associated with conventional cancer treatments Synergistic potential — DMSO demonstrates promising results when combined with various pharmaceutical agents, amplifying their cancer-fighting capabilities